Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Coagulation Stories

2013-07-23 08:31:23

Intellectual Property and Drug Development Opportunity Acquisition Part of Buderer Drug Company Asset Purchase Agreement SAN DIEGO, July 23, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), which is focused on the commercialization of drug formulations utilizing the FDA 505(b)(2) drug development pathway, today announced that as part of the recently announced Buderer Drug Company Asset Purchase Agreement, Imprimis acquired intellectual property for IPI-120, a novel...

2013-07-08 04:21:59

Phase III PROTECT VIII Kids Trial will Evaluate the Pharmacokinetics, Safety and Efficacy of BAY94-9027 for Prophylaxis and Treatment of Bleeding in Previously Treated Children with Severe Hemophilia A WAYNE, N.J., July 8, 2013 /PRNewswire/ -- Bayer HealthCare today announced the company has started to enroll patients in an international Phase II/III trial to evaluate its investigational compound BAY94-9027 for the treatment of hemophilia A in children. The PROTECT VIII (PROphylaxis...

2013-07-04 12:21:48

DUBLIN, July 4, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/wrjhsx/coagulation) has announced the addition of the "Coagulation Diagnostic Testing Markets" [http://www.researchandmarkets.com/research/wrjhsx/coagulation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Coagulation testing, which encompasses both laboratory and point of care (POC) testing, will continue to be one of the...

2013-07-03 12:23:57

Data Presentations at ISTH Highlight Impact of Hemophilia on Health Care Utilization PLAINSBORO, N.J., July 3, 2013 /PRNewswire/ -- Novo Nordisk today announced findings from the Hemophilia Experiences, Results, and Opportunities (HERO) study showing that bleed frequency and treatment regimen choice impacted the use of health care resources and comprehensive care services among adults living with hemophilia. These results were presented in an oral presentation at the XXIV Congress of...

2013-07-03 12:23:55

Recombinant albumin fusion platform forms basis of innovation AMSTERDAM, July 3, 2013 /PRNewswire/ -- CSL Behring today presented Phase I data of their recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP) in healthy volunteers at the International Society on Thrombosis and Haemostasis (ISTH) congress in Amsterdam. (Logo: http://photos.prnewswire.com/prnh/20130627/NY39350LOGO ) CSL Behring, in collaboration with its parent company, CSL Limited (ASX:...

2013-07-03 12:23:53

Recombinant albumin fusion platform forms basis of innovation AMSTERDAM, July 3, 2013 /PRNewswire/ -- CSL Behring today presented a population pharmacokinetic model for recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) at the International Society on Thrombosis and Haemostasis (ISTH) congress in Amsterdam. The model confirms earlier results from the first-in-human dose escalation trial, which demonstrated improved pharmacokinetics of rIX-FP, with...

Tick Saliva New Insight Into Blood Clotting
2013-07-03 09:21:15

Rebekah Eliason for redOrbit.com - Your Universe Online Scientists recently uncovered a surprising potential connection between tick saliva and treatment for heart disease and stroke. Ixodes ticks, commonly known as deer ticks or blacklegged ticks, contain a specific protein in their spit that links to treatment for these diseases. These ticks have also long been known as transmitters of a variety of diseases, including Lyme disease. Deer ticks burrow into the skin of their host and...

2013-07-03 08:25:12

Results of Phase I/II PROLONG-9FP trial program also demonstrate efficacy in treatment of bleeding episodes and improved pharmacokinetics of rIX-FP compared to current treatment options; recombinant albumin fusion platform forms basis of innovation AMSTERDAM, July 3, 2013 /PRNewswire/ -- Data presented by CSL Behring today showed clinical efficacy of a once-weekly dosing regimen of recombinant fusion protein linking coagulation Factor IX with albumin (rIX-FP). Results of the study...

2013-07-03 08:24:34

--New Data Show a Simple Subcutaneous Injection of Factor VIIa-CTP Could Potentially Replace Current Therapies Administered Via Infusion-- AMSTERDAM and NES-ZIONA, Israel, July 3, 2013 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present new results from preclinical studies of its long-acting clotting factor VIIa (Factor VIIa-CTP), a next-generation investigational therapy in advanced preclinical development for the potential treatment...

2013-07-02 12:29:48

Pharmacokinetic results indicate rVIII-SingleChain may have advantages over multi-chain rFVIII AMSTERDAM, July 2, 2013 /PRNewswire/ -- CSL Behring today announced that pharmacokinetic results for its novel investigational recombinant coagulation single-chain factor VIII (rVIII-SingleChain) showed improved half-life over octocog alfa (the comparator). It also demonstrated a safety and efficacy profile that supports advancement to late-stage clinical development. The data were...